Opportunity Information: Apply for PA 13 221
Apply for PA 13 221
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "The Effects of Modulating Chronic Low Grade Inflammation on Geriatric Conditions Secondary Data and/or Biospecimen Analyses and Ancillary Studies in Ongoing or Completed Clinical Trials (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866 Aging Research.
- This funding opportunity was created on May 3, 2013 and posted on May 3, 2013.
- Applicants must submit their applications by Sep 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Independent school districts State governments Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities County governments Special district governments City or township governments For profit organizations other than small businesses Private institutions of higher education Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This NIH grant opportunity (PA-13-221) is an R01 research grant from the National Institutes of Health focused on aging research (CFDA 93.866) and, more specifically, on how chronic, low-grade inflammation affects common geriatric conditions. The program is aimed at researchers who can use existing resources from clinical trials that are already underway or have been completed, rather than proposing entirely new trials from scratch. In practical terms, the FOA is looking for projects that will conduct secondary analyses of previously collected clinical trial data and/or perform new measurements and investigations using stored biospecimens (for example, blood or other biological samples) that were collected during those trials. The overall goal is to extract additional, high-value scientific insights about inflammation, anti-inflammatory interventions, and late-life outcomes by leveraging investments that have already been made in clinical trials.
The central scientific theme is modulating inflammation in older adults and evaluating what that means for aging-related health problems. The FOA highlights geriatric conditions where inflammation may play a role, including functional decline, mobility disability, fatigue, falls, cognitive decline or dementia, and chronic pain. Applications are encouraged to ask questions such as whether inflammatory pathways predict these outcomes, whether anti-inflammatory agents change trajectories of decline, and which subgroups of older individuals may benefit or be harmed. A notable emphasis is that both beneficial and harmful effects matter. In other words, the FOA is not only interested in evidence that lowering inflammation improves function or cognition, but also in potential downsides, tradeoffs, or safety signals that could emerge when inflammation is altered in older people, who often have complex comorbidities and different risk profiles than younger populations.
A major priority area is producing results that can directly inform the design of future intervention studies. The announcement explicitly signals interest in analyses that help answer the kinds of practical questions needed to plan the next generation of trials: which inflammatory markers are most useful as predictors or intermediate outcomes, what dosing windows or treatment durations might be most plausible, which clinical endpoints are sensitive and meaningful in older adults, and which populations should be targeted (or avoided) based on risk and likelihood of benefit. This “trial-design informing” angle is important because it steers applicants toward work that moves beyond descriptive associations and toward evidence that can shape real-world interventional strategies.
In addition to outcomes-focused analyses, the FOA also welcomes mechanistic work that uses existing trial data and biospecimens to understand how chronic, low-grade inflammation may accelerate aging-related decline at a biological level. That includes studies aimed at clarifying the underlying pathophysiologic processes linking inflammation to functional deterioration and other geriatric syndromes, and identifying pathways that might be disrupted by interventions. Mechanistic projects might, for example, explore relationships between inflammatory biomarkers and downstream systems relevant to aging (such as musculoskeletal function, vascular health, neurodegeneration-related processes, pain signaling, or energy metabolism), provided the work is anchored in data and samples from clinical trials involving inflammation or anti-inflammatory agents.
From an operational standpoint, the opportunity is categorized as discretionary funding using the NIH grant mechanism (R01). It does not require cost sharing or matching. The FOA was posted May 3, 2013, with an original and final closing date of September 7, 2016, and an archive date of October 8, 2016, meaning it is no longer open for new submissions under that specific announcement. Even so, it serves as a clear example of the NIH and National Institute on Aging’s priorities around inflammation biology in late life, reuse of clinical trial resources, and the development of evidence that can guide subsequent interventional research.
Eligibility is broad and includes many types of U.S. organizations and government entities, such as small businesses, for-profit organizations (other than small businesses), nonprofits with and without 501(c)(3) status, public and private institutions of higher education, independent school districts, and various levels of government (state, county, city/township, special district), as well as public housing authorities and tribal governments or tribal organizations. The FOA also explicitly includes a wide range of mission- or population-focused institutions (for example, HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISI institutions), along with faith-based and community-based organizations. Foreign organizations and foreign institutions are eligible, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined by NIH policy, reflecting NIH’s openness to international collaboration when scientifically justified.
The simplest way to think about this FOA is that it is trying to accelerate progress on geriatric outcomes by mining existing clinical trials for deeper answers about inflammation. Instead of funding a brand-new intervention trial outright, it supports well-justified add-on studies and sophisticated secondary analyses that can reveal who benefits, who is harmed, what biological pathways are involved, and what future trials should look like to responsibly and effectively test inflammation-modulating strategies in older adults. For full details, the archived announcement is available through the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PA-13-221.html, and the NIH Office of Extramural Research web contacts are listed for technical access or linking issues.
Frequently Asked Questions (FAQs)
What is NIH PA-13-221?
PA-13-221 is an archived National Institutes of Health (NIH) funding opportunity announcement (FOA) for an R01 research grant focused on aging research. It specifically targets research on how chronic, low-grade inflammation influences common geriatric conditions.
What is the CFDA number associated with this opportunity?
The opportunity is associated with CFDA 93.866.
What is the primary scientific focus of this FOA?
The central theme is understanding and modulating chronic, low-grade inflammation in older adults and evaluating how that relates to aging-related health problems and late-life outcomes.
What types of studies does this FOA prioritize?
This FOA prioritizes research that leverages existing resources from clinical trials that are already underway or have been completed. It emphasizes secondary analyses of previously collected clinical trial data and new measurements or investigations using stored biospecimens collected during those trials.
Does this FOA support proposing a brand-new clinical trial?
The emphasis is not on proposing entirely new trials from scratch. Instead, the FOA focuses on extracting additional scientific value from existing clinical trial datasets and stored biospecimens.
What kinds of existing resources are expected to be used?
Applications are expected to rely on previously collected clinical trial data and/or stored biospecimens (for example, blood or other biological samples) that were collected during clinical trials involving inflammation or anti-inflammatory agents.
What geriatric conditions are highlighted as relevant outcomes?
The FOA highlights several geriatric conditions where inflammation may play a role, including functional decline, mobility disability, fatigue, falls, cognitive decline or dementia, and chronic pain.
What types of research questions does the FOA encourage?
Examples include whether inflammatory pathways predict late-life outcomes, whether anti-inflammatory agents change trajectories of decline, and which subgroups of older individuals may benefit or be harmed by inflammation-modulating strategies.
Why does the FOA emphasize both beneficial and harmful effects?
The FOA explicitly values evidence of both potential benefits and potential downsides, tradeoffs, or safety signals when inflammation is altered in older adults, who may have complex comorbidities and different risk profiles than younger populations.
What is meant by the FOA being "trial-design informing"?
A major priority is generating results that can directly inform the design of future intervention studies. The FOA signals interest in analyses that help answer practical trial-planning questions, such as which inflammatory markers are most useful, what treatment windows or durations are plausible, which endpoints are meaningful in older adults, and which populations should be targeted or avoided.
Does the FOA accept mechanistic research projects?
Yes. In addition to outcomes-focused analyses, the FOA welcomes mechanistic work using existing clinical trial data and biospecimens to understand biological processes linking chronic, low-grade inflammation to aging-related decline.
What kinds of mechanistic topics fit within scope?
Mechanistic examples mentioned include exploring relationships between inflammatory biomarkers and downstream systems relevant to aging, such as musculoskeletal function, vascular health, neurodegeneration-related processes, pain signaling, or energy metabolism, as long as the work is anchored in clinical trial data and samples.
What grant mechanism is used for this opportunity?
The FOA uses the NIH R01 research project grant mechanism.
Is this considered discretionary funding?
Yes. The opportunity is described as discretionary funding using the NIH grant mechanism (R01).
Is cost sharing or matching required?
No. The FOA does not require cost sharing or matching.
Is PA-13-221 still open for new submissions?
No. The FOA is archived and is no longer open for new submissions under that specific announcement.
When was the FOA posted and when did it close?
The FOA was posted on May 3, 2013. It had an original and final closing date of September 7, 2016, and an archive date of October 8, 2016.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S. organizations and government entities, such as small businesses, for-profit organizations (other than small businesses), nonprofits with and without 501(c)(3) status, public and private institutions of higher education, independent school districts, and various levels of government (state, county, city/township, special district). It also includes public housing authorities and tribal governments or tribal organizations.
Are mission- or population-focused institutions included in eligibility?
Yes. The FOA explicitly includes institutions such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISI institutions, along with faith-based and community-based organizations.
Are foreign organizations or international components allowed?
Yes. Foreign organizations and foreign institutions are eligible, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined by NIH policy, supporting international collaboration when scientifically justified.
What is the overall goal of the FOA?
The overall goal is to extract additional, high-value scientific insights about inflammation, anti-inflammatory interventions, and late-life outcomes by leveraging investments already made in clinical trials.
Where can the archived FOA be found?
The archived announcement is available through the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PA-13-221.html.
Where can applicants find NIH contacts for technical access or linking issues?
The information provided indicates that NIH Office of Extramural Research web contacts are listed for technical access or linking issues in connection with the archived announcement.
Browse more opportunities from the same category: Health
Next opportunity: Afghanistan Enhancing Civil Societys Advocacy and Monitoring Capacity
Previous opportunity: DoD Neurofibromatosis Exploration Hypothesis Development Award
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 13 221
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 13 221) also looked into and applied for these:
| Funding Opportunity |
|---|
| Sodium Reduction in Communities Apply for CDC RFA DP13 1301 Funding Number: CDC RFA DP13 1301 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
| Native Hawaiian Health Care Improvement Act Apply for HRSA 13 238 Funding Number: HRSA 13 238 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Improving state and local capacity to assess and manage risks associated with private wells and other small drinking water systems by using the Environmental Health Specialist Network (EHS Net) Apply for CDC RFA EH13 1301 Funding Number: CDC RFA EH13 1301 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $175,000 |
| Centers for Disease Control and Prevention Public Health Preparedness and Response Research to Aid Recovery from Hurricane Sandy Apply for RFA TP 13 001 Funding Number: RFA TP 13 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $608,000 |
| Campus Suicide Prevention Grant Apply for SM 13 009 Funding Number: SM 13 009 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $102,000 |
| Implementation of Essentials for Childhood Safe, Stable, Nurturing Relationships and Environments Apply for CDC RFA CE13 1303 Funding Number: CDC RFA CE13 1303 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Grants for Injury Control Research Centers Apply for RFA CE 14 001 Funding Number: RFA CE 14 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $900,000 |
| Grants to States to Support Health Insurance Rate Review and Increase Transparency in Health Care Pricing, Cycle III Apply for PR PRP 13 001 Funding Number: PR PRP 13 001 Agency: CMS Consumer Information Insurance Oversight Category: Health Funding Amount: $5,000,000 |
| National Cooperative Reprogrammed Cell Research Groups (NCRCRG) to Study Mental Illness (U19) Apply for PAR 13 225 Funding Number: PAR 13 225 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improvement of Animal Models and Development of Technologies for Stem Cell Based Regenerative Medicine (SBIR)(R43/R44) Apply for PA 13 223 Funding Number: PA 13 223 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improvement of Animal Models and Development of Technologies for Stem Cell Based Regenerative Medicine (STTR)(R41/R42) Apply for PA 13 224 Funding Number: PA 13 224 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition Mental Health Research Network II (U19) Apply for RFA MH 14 110 Funding Number: RFA MH 14 110 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Innovative Partnerships for Addressing Obesity through Environmental Supports for Nutrition and Physical Activity Apply for CDC RFA DP13 1304 Funding Number: CDC RFA DP13 1304 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Limited Competition Enhancing Investments in Comparative Effectiveness Research Resources (R01) Apply for RFA HS 13 011 Funding Number: RFA HS 13 011 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $750,000 |
| National Technical Assistance Resource Center for the Prevention of Sexual Violence Apply for CDC RFA CE13 1306 Funding Number: CDC RFA CE13 1306 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| SLEEP AND SLEEP DISORDER Apply for CDC RFA DP13 1306 Funding Number: CDC RFA DP13 1306 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
| It Takes a Village Building State, Local, Tribal, and Territorial Partnerships for Community Preparedness and Response Apply for CDC RFA CE13 1308 Funding Number: CDC RFA CE13 1308 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Functional Glycomics in HIV Vaccine Design (R01) Apply for RFA AI 12 056 Funding Number: RFA AI 12 056 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Making Disasters Less Disastrous Public Health, Healthcare Executives, and Emergency Management Working Together Apply for CDC RFA CE13 1309 Funding Number: CDC RFA CE13 1309 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Pan American Health Organization (PAHO) Building Capacity and Networks to Address Emerging Infectious Diseases in the Americas Apply for CDC RFA CK13 1301 Funding Number: CDC RFA CK13 1301 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 13 221", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.